The Asia Pacific Protein Therapeutics Market would witness market growth of 7.7% CAGR during the forecast period (2022-2028).
Protein treatments represent a promising market due to their numerous benefits over small-molecule medications. They are frequently well absorbed and less prone to disrupt regular biological functions. Protein therapies are frequently utilized to treat a variety of disorders including diabetes, and multiple sclerosis due to their high specificity and low immunogenicity. Protein is a crucial part of every living creature. One or more polypeptide chains consisting of amino acids make up each protein molecule.
Peptide bonds are used to connect various amino acid sequences to create protein chains. Each amino acid in a protein is in a specific order. Protein structures are necessary for all of their functions. Proteins carry out a variety of biological tasks within animals, including enzyme defense, catalysis, transport, support, mobility, and control, even though DNA or RNA encodes the information required for life.
The main method of obtaining a particular protein in the past was to isolate it from any natural source, which is typically ineffective and time-consuming. It is now also feasible to replicate the DNA encoding a particular protein into an expression vector to express the protein in expression systems including bacteria, insect cells, yeast, and mammalian cells owing to recent developments in recombinant molecular biology techniques. Recombinant proteins, to put it simply, are the translated by-products of exogenous DNA in live cells.
One of the major reasons that are increasing the adoption of protein therapeutics in the region is the growing geriatric population within regional countries. A wide range of chronic illnesses with a decreased quality of life for the elderly are mostly brought on by aging. According to the National Library of Medicine, Chinese residents made up 18% of the global population in 2019, with 164.5 million of them being 65 or older and 26 million being 80 or older. China has an aging population, and as it does, the strain on the nation's family and public healthcare systems will only become worse.
The China market dominated the Asia Pacific Protein Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $39,387.6 million by 2028. The Japan market is estimated to witness a CAGR of 7% during (2022 - 2028). Additionally, The India market is anticipated to grow a CAGR of 8.3% during (2022 - 2028).
Based on Product, the market is segmented into Monoclonal Antibodies, Human Growth Hormone, Fusion Protein, Insulin, Erythropoietin, Interferon and Follicle Stimulating Hormone. Based on Application, the market is segmented into Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Protein Therapeutics Market is Projected to reach USD 490.2 Billion by 2028, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Baxter International, Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Pfizer, Inc., Novo Nordisk A/S and Sanofi S.A.
By Product
By Application
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 